Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1992 May;45(5):405–407. doi: 10.1136/jcp.45.5.405

Serum myoglobin and creatine kinase enzymes in acute myocardial infarction treated with Anistreplase.

D A McCullough 1, P G Harrison 1, J M Forshall 1, J B Irving 1, R J Hillman 1
PMCID: PMC495301  PMID: 1597518

Abstract

AIMS: To compare plasma myoglobin concentration and cardiac enzyme activity with electrocardiographic (ECG) changes in two groups of patients (reperfused and non-reperfused) participating in a placebo-controlled randomised double blind trial of treatment of myocardial infarction (MI) with intravenous thrombolytic therapy (Anistreplase). METHODS: Twenty two patients with confirmed MI obeying strict inclusion and exclusion criteria were studied. Plasma myoglobin was measured by radioimmunoassay and creatine kinase enzyme (CK and CKMB) by NAC activated and NAC activated/immunoinhibition methods respectively in all patients before and at frequent intervals after injection of Anistreplase or placebo. Patients were divided into reperfused (R) and non-reperfused (NR) groups on the basis of ECG criteria. Reperfusion was diagnosed if the measured ST segment elevation fell by greater than or equal to 50% at 2 hours post dosing. RESULTS: The time to peak (TTP) myoglobin was significantly less in the R group compared with the NR group but there was considerable overlap in the range of values. The area under the enzyme time curves (AUCs) and summed ST segment epsilon ST elevations were significantly smaller in the R compared with the NR group. CONCLUSIONS: Although TTP myoglobin results were significantly lower in the R group, TTP myoglobin will probably not be useful as an non-invasive indicator of reperfusion because of the overlap in values between the two groups. The significant reduction in the AUC and epsilon ST only in the R group suggests decreased infarct size. However, in this small preliminary study reperfusion did not occur more frequently with Anistreplase than without.

Full text

PDF
405

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson J. L., Marshall H. W., Bray B. E., Lutz J. R., Frederick P. R., Yanowitz F. G., Datz F. L., Klausner S. C., Hagan A. D. A randomized trial of intracoronary streptokinase in the treatment of acute myocardial infarction. N Engl J Med. 1983 Jun 2;308(22):1312–1318. doi: 10.1056/NEJM198306023082202. [DOI] [PubMed] [Google Scholar]
  2. Been M., de Bono D. P., Muir A. L., Boulton F. E., Hillis W. S., Hornung R. Coronary thrombolysis with intravenous anisoylated plasminogen-streptokinase complex BRL 26921. Br Heart J. 1985 Mar;53(3):253–259. doi: 10.1136/hrt.53.3.253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Califf R. M., O'Neil W., Stack R. S., Aronson L., Mark D. B., Mantell S., George B. S., Candela R. J., Kereiakes D. J., Abbottsmith C. Failure of simple clinical measurements to predict perfusion status after intravenous thrombolysis. Ann Intern Med. 1988 May;108(5):658–662. doi: 10.7326/0003-4819-108-5-658. [DOI] [PubMed] [Google Scholar]
  4. Ellis A. K., Little T., Zaki Masud A. R., Klocke F. J. Patterns of myoglobin release after reperfusion of injured myocardium. Circulation. 1985 Sep;72(3):639–647. doi: 10.1161/01.cir.72.3.639. [DOI] [PubMed] [Google Scholar]
  5. Hackel D. B., Reimer K. A., Ideker R. E., Mikat E. M., Hartwell T. D., Parker C. B., Braunwald E. B., Buja M., Gold H. K., Jaffe A. S. Comparison of enzymatic and anatomic estimates of myocardial infarct size in man. Circulation. 1984 Nov;70(5):824–835. doi: 10.1161/01.cir.70.5.824. [DOI] [PubMed] [Google Scholar]
  6. Hackworthy R. A., Sorensen S. G., Fitzpatrick P. G., Barry W. H., Menlove R. L., Rothbard R. L., Anderson J. L. Effect of reperfusion on electrocardiographic and enzymatic infarct size: results of a randomized multicenter study of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) versus intracoronary streptokinase in acute myocardial infarction. Am Heart J. 1988 Oct;116(4):903–914. doi: 10.1016/0002-8703(88)90140-8. [DOI] [PubMed] [Google Scholar]
  7. Hogg K. J., Hornung R. S., Howie C. A., Hockings N., Dunn F. G., Hillis W. S. Electrocardiographic prediction of coronary artery patency after thrombolytic treatment in acute myocardial infarction: use of the ST segment as a non-invasive marker. Br Heart J. 1988 Oct;60(4):275–280. doi: 10.1136/hrt.60.4.275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ikram S., Lewis S., Bucknall C., Sram I., Thomas N., Vincent R., Chamberlain D. Treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex. Br Med J (Clin Res Ed) 1986 Sep 27;293(6550):786–789. doi: 10.1136/bmj.293.6550.786. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. MacLennan B. A., McMaster A., Webb S. W., Khan M. M., Adgey A. A. High dose intravenous streptokinase in acute myocardial infarction--short and long term prognosis. Br Heart J. 1986 Mar;55(3):231–239. doi: 10.1136/hrt.55.3.231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. de Zwaan C., Willems G. M., Vermeer F., Res J., Verheugt F. W., van der Laarse A., Simoons M. L., Lubsen J., Hermens W. T. Enzyme tests in the evaluation of thrombolysis in acute myocardial infarction. Br Heart J. 1988 Feb;59(2):175–183. doi: 10.1136/hrt.59.2.175. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES